Drug Type Small molecule drug |
Synonyms LP-A, LP-X, LX-A + [50] |
Target |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Drug Highest PhaseApproved |
First Approval Date JP (01 Mar 1986), |
RegulationPriority Review (CN) |
Molecular FormulaC15H20NaO4 |
InChIKeyNGHFIMBWFYJBHQ-UHFFFAOYSA-N |
CAS Registry226721-96-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01709 | Loxoprofen Sodium Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pain, Postoperative | KR | 03 Apr 2024 | |
Inflammation | JP | 01 Mar 1986 | |
Pain | JP | 01 Mar 1986 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pain, Postoperative | Phase 3 | CN | 11 Apr 2024 | |
Pain, Postoperative | Phase 3 | CN | 11 Apr 2024 | |
Post procedural inflammation | Phase 3 | CN | 11 Apr 2024 | |
Post procedural inflammation | Phase 3 | CN | 11 Apr 2024 | |
Cataract | Phase 2 | CN | 30 Dec 2022 | |
Inflammation | Phase 2 | CN | 30 Dec 2022 | |
Inflammation | Phase 2 | CN | 30 Dec 2022 | |
Osteoarthritis, Knee | Phase 1 | CN | 10 Apr 2017 | |
Myalgia | Phase 1 | US | 01 Oct 2015 | |
Wounds and Injuries | Phase 1 | BR | 01 Oct 2015 |
Not Applicable | 451 | (People living with HIV) | khibybxunm(nuxhuzwyrp) = bqgucxaemr hxuzqmvijj (huvcsedite, 5.1 - 36) | - | 01 Jan 2022 | ||
Phase 2 | 47 | (Experimental) | beccmmyctp(kqhneepbif) = zkyndtjfpo ogybvutznq (owalhmrhxl, alhzdlqncn - qozaqaorwi) View more | - | 09 Sep 2019 | ||
(Placebo Comparator) | beccmmyctp(kqhneepbif) = ydwdjbvmjm ogybvutznq (owalhmrhxl, fylpxzrake - vugqxrvkgo) View more | ||||||
Phase 3 | 80 | jipdyoztkt(qtnoecqvzg) = ywsbrqdomy itqgewtgmh (mkztsaypto, tcgwojjiia - mpatzukmcp) View more | - | 20 Jul 2018 | |||
Phase 4 | First line | 190 | (xpmlzumngk) = zzogcnllka vpgopvubby (ppjodqfpob ) | Positive | 01 Feb 2013 | ||
(xpmlzumngk) = fbeyskasfd vpgopvubby (ppjodqfpob ) |